Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amphastar Pharmaceuticals Inc AMPH

Healthcare
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed... see more

Recent & Breaking News (NDAQ:AMPH)

Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference

Accesswire August 28, 2024

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024

Accesswire August 7, 2024

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024

Accesswire July 31, 2024

Amphastar Announces Additional $50 Million Increase to its Share Buyback Program

Accesswire June 4, 2024

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Accesswire June 3, 2024

Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

Accesswire May 22, 2024

Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference

Accesswire May 9, 2024

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024

Accesswire May 8, 2024

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024

Accesswire April 30, 2024

Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

Accesswire April 1, 2024

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

Accesswire March 6, 2024

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023

Accesswire February 28, 2024

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024

Accesswire February 20, 2024

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Accesswire January 2, 2024

Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Accesswire November 20, 2023

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Accesswire November 9, 2023

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023

Accesswire November 8, 2023

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023

Accesswire November 1, 2023

Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes

Accesswire September 13, 2023

Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes

Accesswire September 11, 2023